The Archive · 3 posts
Elevating healthcare solutions 🔍 Smith & Nephew (SN) is a leader in medical technology, innovating at the LSE. Discover what sets them apart! 🌟
Smith+Nephew Q1 2026: 3.1% underlying growth, $500M buyback, guidance unchanged. Sports medicine strong, US knees weak but no nasty surprises.
May 6, 2026
Showing 2 of 3 posts
Smith+Nephew’s 2025 results show strong growth and margin expansion, completing its turnaround. New RISE strategy targets 2028 growth acceleration and $1bn+ cash flow.
JoshuaMarch 2, 2026
Smith & Nephew reports strong H1 2025 results: 5% revenue growth, $500M share buyback, and $244M free cash flow surge amid accelerating growth.
JoshuaAugust 5, 2025